年龄改变了HBVDNA水平与妊娠期间肝功能障碍风险之间的关联
Xingran Tao1, Wenjing Yu1, Qiao Yan1
1Department of Obstetrics and Gynecology, the Second Hospital of Nanjing, and Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
Journal of viral hepatitis
|September 9, 2025
概括
在患有慢性乙型肝炎病毒 (HBV) 感染的孕妇中,较高的HBVDNA水平与老年母亲的氨酸转移酶 (ALT) 升高有关. 年龄会影响这种关联,需要量身定制的监测以获得更好的结果.
科学领域:
- 肝病学和病毒学.
- 孕产妇和胎儿医学 孕产妇和胎儿医学
- 公共卫生 公共卫生
背景情况:
- 乙型肝炎病毒 (HBV) 感染对全球健康构成风险,特别是在怀孕期间.
- 孕妇的慢性HBV感染需要谨慎管理,因为可能会导致母亲和胎儿的并发症.
研究的目的:
- 调查 HBV DNA 水平,阿氨酸转移酶 (ALT) 水平和患有慢性 HBV 的孕妇的孕妇年龄之间的关系.
- 评估ALT升高与产科结果之间的关联,考虑到母亲的年龄.
主要方法:
- 一项对1743名感染HBV的孕妇的队列研究.
- 将参与者分为低,中等和高HBVDNA水平的组.
- 修改Poisson回归和线性趋势测试,以分析HBVDNA,ALT水平 (MRALT,RALT) 和产科结果之间的关系,以年龄分层.
主要成果:
- 在35岁以上的孕妇中,更高的HBVDNA水平独立地与更高的ALT (RALT) 升高风险相关,但ALT (MRALT) 升高的风险不是最小的.
- 一个显著的趋势显示,随着HBV DNA水平的升级,RALT风险增加 (p < 0.001).
- 升高的ALT与年轻母亲 (<35岁) 的早产和低出生体重有关,在年长的母亲 (≥35岁) 中观察到类似的趋势,但在统计学上不显著.
结论:
- 母亲年龄显著改变了HBVDNA升高和ALT风险升高之间的关联.
- 根据年龄分层的监测和有针对性的治疗对于患有慢性HBV感染的孕妇来说至关重要,以减轻不良的产科结果.
相关概念视频
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
185
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
185
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
217
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
217
01:07Teratogenicity
4.0K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.0K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
257
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
257
01:19Rh Blood Group
2.8K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
2.8K
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
216
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
216